DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice.
Adamantane
/ administration & dosage
Aged
Aged, 80 and over
Cross-Sectional Studies
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptides
/ administration & dosage
Dipeptidyl-Peptidase IV Inhibitors
/ administration & dosage
Female
General Practice
Humans
Male
Middle Aged
Sitagliptin Phosphate
/ administration & dosage
United Kingdom
DPP-4 inhibitors
Type 2 diabetes mellitus
UK general practice
dose selection
renal impairment
summary of product characteristics
Journal
Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
17
04
2019
revised:
10
05
2019
accepted:
14
05
2019
pubmed:
6
6
2019
medline:
28
5
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting.
Identifiants
pubmed: 31164243
pii: S0149-2918(19)30255-3
doi: 10.1016/j.clinthera.2019.05.010
pii:
doi:
Substances chimiques
Dipeptides
0
Dipeptidyl-Peptidase IV Inhibitors
0
saxagliptin
9GB927LAJW
Adamantane
PJY633525U
Sitagliptin Phosphate
TS63EW8X6F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1622-1630Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.